Quick Answer
Theravance Biopharma, Inc. reported Total Revenue of $107.46 million for fiscal year 2025.
Theravance Biopharma, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $107.46M | +66.9% |
| 2024 | $64.38M | +12.1% |
| 2023 | $57.42M | +11.8% |
| 2022 | $51.35M | -7.2% |
| 2021 | $55.31M | -23.0% |
| 2020 | $71.86M | -2.1% |
| 2019 | $73.41M | +21.6% |
| 2018 | $60.37M | +292.4% |
| 2017 | $15.39M | -68.4% |
| 2016 | $48.65M | +15.5% |
| 2015 | $42.13M | +260.4% |
| 2014 | $11.69M | +5071.7% |
| 2013 | $226.0K | -99.8% |
| 2012 | $130.15M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $19.99M | +18.5% | -23.7% |
| June 30, 2025 | $26.20M | +83.7% | +70.2% |
| March 31, 2025 | $15.39M | +6.1% | -8.8% |
| September 30, 2024 | $16.87M | +7.5% | +18.3% |
| June 30, 2024 | $14.26M | +3.7% | -1.7% |
| March 31, 2024 | $14.50M | +39.2% | -7.6% |
| September 30, 2023 | $15.69M | +26.0% | +14.1% |
| June 30, 2023 | $13.75M | +24.4% | +32.0% |
- Theravance Biopharma, Inc. showed an increase of +66.9% in Total Revenue compared to the prior fiscal year.
- Over the 2012–2025 period, Theravance Biopharma, Inc.’s total revenue has declined by 17.4% (from $130.15 million to $107.46 million).
- The most recent figure is from Theravance Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: